Close
  Indian J Med Microbiol
 

Figure 5: The fate of huMSCs in TBI rats given in situ or tail vein transplantation. (A) Fluorescence staining of CASP3 in the In Situ group. On the first day after the last transplantation, there was no immunoreactivity towards CASP3 (red, stained by CoraLite594, red arrows) in huMSCs (green arrows). huMSCs began to express caspase 3 (denoted by a yellow ellipse) from the third day post final transplantation, indicating that huMSCs began to undergo apoptosis. On the 14th day, almost no huMSCs remained. The neural cells in the injury site can also undergo apoptosis as they express CASP3. (B) Fluorescence staining for F4/80 (red, stained by CoraLite594) in the In Situ group. On the first day after injection of huMSCs, there were some macrophages (red, red arrows) around the CFSE-labeled huMSCs (indicated by green arrows). Over time, more macrophages accumulated, and they persisted up to 12 months later. (C) Fluorescence staining results of CASP3 in the Tail Vein group are similar to those in the In Situ group. (D) Fluorescence staining results of F4/80 in the Tail Vein group are similar to those in the In Situ group. However, the number of macrophages in the Tail Vein group was less than that in the In Situ group, especially on the 14th day. Cells indicated by yellow arrows are red cells that exhibit autofluorescence (original magnification 400×, scale bar: 50 μm). CASP3: Caspase 3; CFSE: carboxyfluorescein succinimidyl ester; huMSCs: human umbilical cord mesenchymal stem cells; TBI: traumatic brain injury.

Figure 5: The fate of huMSCs in TBI rats given <i>in situ</i> or tail vein transplantation.
(A) Fluorescence staining of CASP3 in the <i>In Situ</i> group. On the first day after the last transplantation, there was no immunoreactivity towards CASP3 (red, stained by CoraLite594, red arrows) in huMSCs (green arrows). huMSCs began to express caspase 3 (denoted by a yellow ellipse) from the third day post final transplantation, indicating that huMSCs began to undergo apoptosis. On the 14<sup>th</sup> day, almost no huMSCs remained. The neural cells in the injury site can also undergo apoptosis as they express CASP3. (B) Fluorescence staining for F4/80 (red, stained by CoraLite594) in the <i>In Situ</i> group. On the first day after injection of huMSCs, there were some macrophages (red, red arrows) around the CFSE-labeled huMSCs (indicated by green arrows). Over time, more macrophages accumulated, and they persisted up to 12 months later. (C) Fluorescence staining results of CASP3 in the Tail Vein group are similar to those in the <i>In Situ</i> group. (D) Fluorescence staining results of F4/80 in the Tail Vein group are similar to those in the <i>In Situ</i> group. However, the number of macrophages in the Tail Vein group was less than that in the <i>In Situ</i> group, especially on the 14<sup>th</sup> day. Cells indicated by yellow arrows are red cells that exhibit autofluorescence (original magnification 400×, scale bar: 50 μm). CASP3: Caspase 3; CFSE: carboxyfluorescein succinimidyl ester; huMSCs: human umbilical cord mesenchymal stem cells; TBI: traumatic brain injury.